Dyphylline Disease Interactions

Dyphylline is eliminated almost entirely by the kidney. Drug accumulation may occur in patients with impaired renal function. Like other methylxanthines, high plasma levels of the drug may be associated with severe cardio- and neurotoxicity, sometimes without any previous warning. Therapy with dyphylline should be administered cautiously in patients with renal impairment. Dosage adjustments may be necessary. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.

Methylxanthines are known to stimulate peptic acid secretion. Therapy with products containing methylxanthines should be administered with extreme caution in patients with active peptic ulcer disease. Some manufacturers consider their use to be contraindicated under such circumstance.

Like other methylxanthines, dyphylline at high dosages may be associated with positive inotropic and chronotropic effects on the heart. Therapy with dyphylline and products containing dyphylline should be administered cautiously in patients with severe cardiac disease, hypertension, hyperthyroidism, or recent myocardial infarction. The relationship between plasma dyphylline levels and therapeutic as well as toxic effects has not been determined.

Methylxanthines increase gastric acidity and may also relax lower esophageal sphincter, which can lead to gastric reflux into the esophagus. Therapy with products containing methylxanthines should be administered cautiously in patients with significant gastroesophageal reflux.